Secukinumab is effective and safe in the long‐term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients

Chicharro, Pablo; Llamas‐Velasco, Mar; Armesto, Susana; Herrera‐Acosta, Enrique; Vidal, David; Vilarrasa, Eva; Rivera, R.; Cueva, Pablo de la; Martorell, A.; Ballescá, F.; Belinchón, I.; Carretero, G.; Rodríguez, Lourdes; Romero‐Maté, Alberto; Pujol-Montcusí, Josep; Salgado, L.; Sahuquillo‐Torralba, Antonio; Coto‐Segura, Pablo; Baniandrés, Ofelia; Feltes, Rosa; Riera‐Monroig, Josep; Daudén, E.

doi:10.1111/dth.15929

Cited by 3 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to our findings, BMI was an independent variable as a predictor of PASI 90 and PASI 100 response after 12 weeks of treatment. When dividing our subjects into two subgroups (BMI ≥25 kg/m 2 and BMI < 25 kg/m 2 ), the difference in effectiveness was more significant, which was reported by Chicharro et al likewise 10 . Similarly, patients with BMI ≤25 kg/m 2 would more likely achieve PASI 90 and absolute PASI value <3 at month 18 in a recent study with long‐term treatment conducted by Pablo Chicharro in Spain 10 .…”

Section: Discussionsupporting

confidence: 51%

“…When dividing our subjects into two subgroups (BMI ≥25 kg/m 2 and BMI < 25 kg/m 2 ), the difference in effectiveness was more significant, which was reported by Chicharro et al likewise. 10 Similarly, patients with BMI ≤25 kg/m 2 would more likely achieve PASI 90 and absolute PASI value <3 at month 18 in a recent study with long-term treatment conducted by Pablo Chicharro in Spain. 10 Some other real-world studies reported that BMI ≥30 kg/m 2 was related to poorer response.…”

Section: Exploratory Analysis Of Covid-19 Vaccination and Infectionmentioning

confidence: 94%

“…10 Similarly, patients with BMI ≤25 kg/m 2 would more likely achieve PASI 90 and absolute PASI value <3 at month 18 in a recent study with long-term treatment conducted by Pablo Chicharro in Spain. 10 Some other real-world studies reported that BMI ≥30 kg/m 2 was related to poorer response. [11][12][13][14] In line with previous studies in other countries reported, the exposure to previous biologic therapies in Chinese patients had a negative impact on PASI responses.…”

Section: Exploratory Analysis Of Covid-19 Vaccination and Infectionmentioning

confidence: 94%

See 2 more Smart Citations

Effectiveness and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis in real‐world practice

Zhou

Yuan

Liu

et al. 2023

Experimental Dermatology

View full text Add to dashboard Cite

A number of randomized controlled trials and real‐world studies have demonstrated the effectiveness and safety of secukinumab in the treatment of moderate to severe psoriasis, whereas data on a large cohort of Chinese patients in long‐term real‐world practice are limited. This was a single‐centre, uncontrolled, single‐arm, prospective, observational cohort study that included 254 psoriatic patients treated with secukinumab between September 2019 and December 2022. Demographic and clinical characteristics of patients, clinical response and adverse events were evaluated. The 75% improvement in Psoriasis Area and Severity Index score (PASI 75), PASI 90, and PASI 100 in the 300 mg secukinumab group at 12 weeks were 91.7%, 74.0% and 39.7% respectively, increasing to 94.5%, 74.5% and 47.6% at 52 weeks. High body mass index (BMI), previous exposure to biologic therapies and history of previous conventional systemic therapies were associated with lower rates of PASI response. During the study period, 68 patients reported 83 adverse events (AEs) and the most frequent AEs were eczematous lesions. Up to 14.5% patients withdrew treatment due to disease remission combined with inconvenient transportation during the COVID‐19 pandemic at 52 weeks. The rate of psoriasis exacerbation after COVID‐19 infection in patients treated with secukinumab was 24.3% (17/70). This real‐world study confirmed the high effectiveness of secukinumab in Chinese patients with moderate to severe plaque psoriasis, with an acceptable safety profile.

show abstract

Section: Discussionsupporting

confidence: 51%

Section: Exploratory Analysis Of Covid-19 Vaccination and Infectionmentioning

confidence: 94%

Section: Exploratory Analysis Of Covid-19 Vaccination and Infectionmentioning

confidence: 94%

See 1 more Smart Citation

Effectiveness and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis in real‐world practice

Zhou

Yuan

Liu

et al. 2023

Experimental Dermatology

View full text Add to dashboard Cite

show abstract

Insulin resistance impairs biologic agent response in moderate-to-severe plaque psoriasis: insights from a prospective cohort study in China

Huang,

Zhong,

Jiang

et al. 2024

British Journal of Dermatology

View full text Add to dashboard Cite

Background Psoriasis and insulin resistance (IR) are closely related, but it remains unclear whether IR affects the treatment of patients with psoriasis. Objective The objective of this study was to investigate whether IR impairs the treatment response to biologic agents in patients with moderate-to-severe plaque psoriasis. Methods This project was based on a prospective cohort study design. Data for this study were collected from the Shanghai Psoriasis Effectiveness Evaluation CoHort (SPEECH), which is a prospective cohort exploring treatment strategies for psoriasis in China. IR was assessed using the triglyceride glucose-body mass index (TyG-BMI). Psoriasis severity was assessed using the Psoriasis Area and Severity Index (PASI) and Physician’s Global Assessment (PGA). Multiple logistic regression was used to explore the differences between patients with high and low levels of IR. Subgroup and sensitivity analyses were performed to examine the robustness of the study results. Results A total of 290 patients were included in the analysis. Based on the median TyG-BMI, the patients were divided into two groups: High and Low. The High group exhibited a higher prevalence of diabetes, higher BMI, fasting blood glucose, and triglyceride compared with the Low group. Further analysis of the treatment efficacy revealed that the High group had lower response rates for PASI 75, PASI 90, and PGA 0/1 after 12 weeks of treatment. In the Low group, 81.94% of patients achieved PASI 75, 58.33% achieved PASI 90, and 75.69% achieved PGA 0/1. However, the proportion of responses at each endpoint was significantly lower in the High group. The impairment in response to PGA 0/1 was more significant in the High group, indicated by lower odd ratios. Subsequent subgroup analysis and sensitivity analysis produced consistent results. Conclusion IR is associated with lower effectiveness of biologics in patients with psoriasis. Clinical trial registration [www.chictr.org.cn], identifier [ChiCTR2000036186]

show abstract

Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real‐life clinical practice

Muñoz‐Aceituno,

Butrón‐Bris,

Ovejero‐Benito

et al. 2023

Acad Dermatol Venereol

View full text Add to dashboard Cite

BackgroundPrediction of the response to a biological treatment in psoriasis patients would allow efficient treatment allocation.ObjectiveTo identify polymorphisms associated with secukinumab response in psoriasis patients in a daily practice setting.MethodsWe studied 180 SNPs in patients with moderate‐to‐severe plaque psoriasis recruited from 15 Spanish hospitals. Treatment effectiveness was evaluated by absolute PASI ≤3 and ≤1 at 6 and 12 months. Individuals were genotyped using a custom Taqman array. Multiple logistic regression models were generated. Sensitivity, specificity and area under the curve (AUC) were analysed.ResultsA total of 173 patients were studied at 6 months, (67% achieved absolute PASI ≤ 3 and 65% PASI ≤ 1) and 162 at 12 months (75% achieved absolute PASI ≤ 3 and 64% PASI ≤ 1). Multivariable analysis showed the association of different sets of SNPs with the response to secukinumab. The model of absolute PASI≤3 at 6 months showed best values of sensitivity and specificity. Four SNPs were associated with the capability of achieving absolute PASI ≤ 3 at 6 months. rs1801274 (FCGR2A), rs2431697 (miR‐146a) and rs10484554 (HLCw6) were identified as risk factors for failure to achieve absolute PASI≤3, while rs1051738 (PDE4A) was protective. AUC including these genotypes, weight of patients and history of biological therapy was 0.88 (95% CI 0.83–0.94), with a sensitivity of 48.6% and specificity of 95.7% to discriminate between both phenotypes.ConclusionWe have identified a series of polymorphisms associated with the response to secukinumab capable of predicting the potential response/non‐response to this drug in patients with plaque psoriasis.

show abstract

Secukinumab is effective and safe in the long‐term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients

Cited by 3 publications

References 23 publications

Effectiveness and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis in real‐world practice

Effectiveness and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis in real‐world practice

Insulin resistance impairs biologic agent response in moderate-to-severe plaque psoriasis: insights from a prospective cohort study in China

Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real‐life clinical practice

Contact Info

Product

Resources

About